The urinary proteome and metabonome differ from normal in adults with mitochondrial disease

Kidney International

Volumn 87, Issue 3, 2015, Pages 610-622

  Hall, Andrew M ^a   Vilasi, Annalisa ^b   Garcia Perez, Isabel ^c   Lapsley, Marta ^d   Alston, Charlotte L ^e   Pitceathly, Robert D S ^f   McFarland, Robert ^e   Schaefer, Andrew M ^e   Turnbull, Doug M ^e   Beaumont, Nick J ^g   Hsuan, Justin J ^g   Cutillas, Pedro R ^h   Lindon, John C ^c   Holmes, Elaine ^c   Unwin, Robert J ⁱ   Taylor, Robert W ^e   Gorman, Grainne S ^e   Rahman, Shamima ^j   Hanna, Michael G ^f  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁱ ROYAL FREE HOSPITAL   (United Kingdom)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

kidney dysfunction; mitochondria; proteinuria

Indexed keywords

ADENINE; ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMITRIPTYLINE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM BINDING PROTEIN; CARBAMAZEPINE; CELL PROTEIN; CLOBAZAM; CREATININE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETIRACETAM; EZETIMIBE; FUROSEMIDE; GABAPENTIN; GUANINE; INSULIN; LYSOSOMAL PROTEIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEOME; PROTON PUMP INHIBITOR; RETINOL BINDING PROTEIN; SEROTONIN UPTAKE INHIBITOR; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; BIOLOGICAL MARKER; LYSOSOMAL PROTEINS; MAGNESIUM; PROTEIN; TRANSFER RNA;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE MUTATION; GLOMERULOPATHY; HETEROZYGOTE; HUMAN; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY DYSFUNCTION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MATERNALLY INHERITED DIABETES AND DEAFNESS; MELAS SYNDROME; MERRF SYNDROME; MITOCHONDRIAL RESPIRATION; NUCLEAR MAGNETIC RESONANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; ADOLESCENT; ALBUMINURIA; BLOOD; CASE CONTROL STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; GENETICS; HEARING IMPAIRMENT; KIDNEY DISEASE; METABOLISM; METABOLOME; MIDDLE AGED; MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALBUMINURIA; ANTIOXIDANTS; BIOMARKERS; CALCIUM-BINDING PROTEINS; CASE-CONTROL STUDIES; CREATININE; CROSS-SECTIONAL STUDIES; DEAFNESS; DIABETES MELLITUS, TYPE 2; HETEROZYGOTE; HUMANS; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY DISEASES; MAGNESIUM; MELAS SYNDROME; MERRF SYNDROME; METABOLOME; MIDDLE AGED; MITOCHONDRIAL DISEASES; MUTATION; PROTEINS; PROTEOME; RETINOL-BINDING PROTEINS; RNA, TRANSFER; YOUNG ADULT;

EID: 84938415681     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.297     Document Type: Article

References (87)

1. McFarland R, Taylor RW, Turnbull DM A neurological perspective on mitochondrial disease. Lancet Neurol. 2010; 9: 829-840
2. Koopman WJ, Willems PH, Smeitink JA. Monogenic mitochondrial disorders. N Engl J Med. 2012; 366: 1132-1141
3. Rahman S, Hall AM. Mitochondrial disease-An important cause of endstage renal failure. Pediatr Nephrol. 2013; 28: 357-361
4. Hotta O, Inoue CN, Miyabayashi S, et al. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int. 2001; 59: 1236-1243
5. Bagnasco S, Good D, Balaban R, et al. Lactate production in isolated segments of the rat nephron. Am J Physiol. 1985; 248: F522-F526
6. Martin-Hernandez E, Garcia-Silva MT, Vara J, et al. Renal pathology in children with mitochondrial diseases. Pediatr Nephrol. 2005; 20: 1299-1305
7. Niaudet P, Rotig A. Renal involvement in mitochondrial cytopathies. Pediatr Nephrol. 1996; 10: 368-373
8. Niaudet P, Rotig A. The kidney in mitochondrial cytopathies. Kidney Int. 1997; 51: 1000-1007
9. Rotig A. Renal disease and mitochondrial genetics. J Nephrol. 2003; 16: 286-292
10. Emma F, Bertini E, Salviati L, et al. Renal involvement in mitochondrial cytopathies. Pediatr Nephrol. 2011; 27: 539-550
11. Manwaring N, Jones MM, Wang JJ, et al. Population prevalence of the MELAS A3243G mutation. Mitochondrion. 2007; 7: 230-233
12. Nesbitt V, Pitceathly RD, Turnbull DM, et al. The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A4G mutation-implications for diagnosis and management. J Neurol Neurosurg Psychiatry. 2013; 84: 936-938
13. DiMauro S, Hirano M. MELAS. In Pagon RA, Bird TD, Dolan CR, et al. (eds) Gene Reviews. University of Washington: Seattle, WA, USA, 2010
14. Dinour D, Mini S, Polak-Charcon S, et al. Progressive nephropathy associated with mitochondrial tRNA gene mutation. Clin Nephrol. 2004; 62: 149-154
15. Doleris LM, Hill GS, Chedin P, et al. Focal segmental glomerulosclerosis associated with mitochondrial cytopathy. Kidney Int. 2000; 58: 1851-1858
16. Fujii H, Mori Y, Kayamori K, et al A familial case of mitochondrial disease resembling Alport syndrome. Clin Exp Nephrol. 2008; 12: 159-163
17. Guery B, Choukroun G, Noel LH, et al. The spectrum of systemic involvement in adults presenting with renal lesion and mitochondrial tRNA(Leu) gene mutation. J Am Soc Nephrol. 2003; 14: 2099-2108
18. Li JY, Hsieh RH, Peng NJ, et al A follow-up study in a Taiwanese family with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes syndrome. J Formos Med Assoc. 2007; 106: 528-536
19. Lowik MM, Hol FA, Steenbergen EJ, et al. Mitochondrial tRNALeu(UUR) mutation in a patient with steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2005; 20: 336-341
20. Guillausseau PJ, Massin P, Dubois-LaForgue D, et al. Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med. 2001; 134: 721-728
21. Massin P, Dubois-LaForgue D, Meas T, et al. Retinal and renal complications in patients with a mutation of mitochondrial DNA at position 3,243 (maternally inherited diabetes and deafness) A casecontrol study. Diabetologia. 2008; 51: 1664-1670
22. Mullen W, Delles C, Mischak H. Urinary proteomics in the assessment of chronic kidney disease. Curr Opin Nephrol Hypertens. 2011; 20: 654-661
23. Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol. 2012; 8: 22-33
24. Nguyen MT, Ross GF, Dent CL, et al. Early prediction of acute renal injury using urinary proteomics. Am J Nephrol. 2005; 25: 318-326
25. Portilla D, Li S, Nagothu KK, et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int. 2006; 69: 2194-2204
26. Xu EY, Perlina A, Vu H, et al. Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology of model nephrotoxicants. Chem Res Toxicol. 2008; 21: 1548-1561
27. Boudonck KJ, Mitchell MW, Nemet L, et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol Pathol. 2009; 37: 280-292
28. Devarajan P, Krawczeski CD, Nguyen MT, et al. Proteomic identification of early biomarkers of acute kidney injury after cardiac surgery in children. Am J Kidney Dis. 2010; 56: 632-642
29. Metzger J, Kirsch T, Schiffer E, et al. Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int. 2010; 78: 1252-1262
30. Aregger F, Uehlinger DE, Witowski J, et al. Identification of IGFBP-7 by urinary proteomics as a novel prognostic marker in early acute kidney injury. Kidney Int. 2013; 85: 909-919
31. Rossing K, Mischak H, Dakna M, et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol. 2008; 19: 1283-1290
32. van der Kloet FM, Tempels FW, Ismail N, et al. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics. 2012; 8: 109-119
33. Sharma K, Karl B, Mathew AV, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol. 2013; 24: 1901-1912
34. Kistler AD, Serra AL, Siwy J, et al. Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One. 2013; 8: e53016
35. Taylor SL, Ganti S, Bukanov NO, et al A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am J Physiol Renal Physiol. 2010; 298: F909-F922
36. Vilasi A, Cutillas PR, Maher AD, et al. Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome. Am J Physiol Renal Physiol. 2007; 293: F456-F467
37. Drube J, Schiffer E, Mischak H, et al. Urinary proteome pattern in children with renal Fanconi syndrome. Nephrol Dial Transplant. 2009; 24: 2161-2169
38. Kind T, Tolstikov V, Fiehn O, et al A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal Biochem. 2007; 363: 185-195
39. Bernard AM, Moreau D, Lauwerys R. Comparison of retinol-binding protein and beta 2-microglobulin determination in urine for the early detection of tubular proteinuria. Clin Chim Acta. 1982; 126: 1-7
40. Norden AG, Scheinman SJ, schodt-Lanckman MM, et al. Tubular proteinuria defined by a study of Dent's (CLCN5 mutation) and other tubular diseases. Kidney Int. 2000; 57: 240-249
41. Quintana LF, Campistol JM, Alcolea MP, et al. Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol Cell Proteomics. 2009; 8: 1658-1673
42. Nicholson JK, Foxall PJ, Spraul M, et al. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem. 1995; 67: 793-811
43. Lindon JC, Nicholson JK, Everett JR. NMR spectroscopy of biofluids. Annu Rep NMR Spectrosc. 1999; 38: 1-88
44. Wishart DS, Jewison T, Guo AC, et al. HMDB 3.0-The Human Metabolome Database in 2013. Nucleic Acids Res. 2013; 41: D801-D807
45. Lees HJ, Swann JR, Wilson ID, et al. Hippurate: the natural history of a mammalian-microbial cometabolite. J Proteome Res. 2013; 12: 1527-1546
46. Hall AM, Unwin RJ, Hanna MG, et al. Renal function and mitochondrial cytopathy (MC): more questions than answers?. QJM. 2008; 101: 755-766
47. Inui K, Fukushima H, Tsukamoto H, et al. Mitochondrial encephalomyopathies with the mutation of the mitochondrial tRNA(Leu(UUR)) gene. J Pediatr. 1992; 120: 62-66
48. Mochizuki H, Joh K, Kawame H, et al. Mitochondrial encephalomyopathies preceded by de-Toni-Debre-Fanconi syndrome or focal segmental glomerulosclerosis. Clin Nephrol. 1996; 46: 347-352
49. Yorifuji T, Kawai M, Momoi T, et al. Nephropathy and growth hormone deficiency in a patient with mitochondrial tRNA(Leu(UUR)) mutation. J Med Genet. 1996; 33: 621-622
50. Hameed R, Raafat F, Ramani P, et al. Mitochondrial cytopathy presenting with focal segmental glomerulosclerosis, hypoparathyroidism, sensorineural deafness, and progressive neurological disease. Postgrad Med J. 2001; 77: 523-526
51. Gucer S, Talim B, Asan E, et al. Focal segmental glomerulosclerosis associated with mitochondrial cytopathy: report of two cases with special emphasis on podocytes. Pediatr Dev Pathol. 2005; 8: 710-717
52. Rotig A, Appelkvist EL, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet. 2000; 356: 391-395
53. Salviati L, Sacconi S, Murer L, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology. 2005; 65: 606-608
54. Lopez LC, Schuelke M, Quinzii CM, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet. 2006; 79: 1125-1129
55. Quinzii C, Naini A, Salviati L, et al A mutation in para-hydroxybenzoatepolyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet. 2006; 78: 345-349
56. Diomedi-Camassei F, Di GS, Santorelli FM, et al. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol. 2007; 18: 2773-2780
57. Heeringa SF, Chernin G, Chaki M, et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest. 2011; 121: 2013-2024
58. Rahman S, Clarke CF, Hirano M. 176th ENMC International Workshop: diagnosis and treatment of coenzyme Q(1)(0) deficiency. Neuromuscul Disord. 2012; 22: 76-86
59. Shoffner JM, Voljavec AS, Dixon J, et al. Renal amino acid transport in adults with oxidative phosphorylation diseases. Kidney Int. 1995; 47: 1101-1107
60. Damian MS, Seibel P, Reichmann H, et al. Clinical spectrum of the MELAS mutation in a large pedigree. Acta Neurol Scand. 1995; 92: 409-415
61. Kim MJ, Frankel AH, Tam FW. Urine proteomics and biomarkers in renal disease. Nephron Exp Nephrol. 2011; 119: e1-e7
62. Nissim I, Horyn O, Daikhin Y, et al. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res. 2006; 66: 7824-7831
63. Good DM, Zurbig P, Argiles A, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics. 2010; 9: 2424-2437
64. Wen M, Segerer S, Dantas M, et al. Renal injury in apolipoprotein E-deficient mice. Lab Invest. 2002; 82: 999-1006
65. Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006; 47: 199-211
66. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011; 12: 9-14
67. Sansanwal P, Sarwal MM. Abnormal mitochondrial autophagy in nephropathic cystinosis. Autophagy. 2010; 6: 971-973
68. Servais H, Van Der Smissen P, Thirion G, et al. Gentamicin-induced apoptosis in LLC-PK1 cells: involvement of lysosomes and mitochondria. Toxicol Appl Pharmacol. 2005; 206: 321-333
69. Al-Bander HA, Mock DM, Etheredge SB, et al. Coordinately increased lysozymuria and lysosomal enzymuria induced by maleic acid. Kidney Int. 1986; 30: 804-812
70. Christensen EI, Maunsbach AB. Proteinuria induced by sodium maleate in rats: effects on ultrastructure and protein handling in renal proximal tubule. Kidney Int. 1980; 17: 771-787
71. Duchen MR, Verkhratsky A, Muallem S. Mitochondria and calcium in health and disease. Cell Calcium. 2008; 44: 1-5
72. Maiza A, Waldek S, Ballardie FW, et al. Estimation of renal tubular secretion in man, in health and disease, using endogenous N-1-methylnicotinamide. Nephron. 1992; 60: 12-16
73. Wang Y, Lawler D, Larson B, et al. Metabonomic investigations of aging and caloric restriction in a life-long dog study. J Proteome Res. 2007; 6: 1846-1854
74. Holmes E, Loo RL, Stamler J, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature. 2008; 453: 396-400
75. Deguchi T, Takemoto M, Uehara N, et al. Renal clearance of endogenous hippurate correlates with expression levels of renal organic anion transporters in uremic rats. J Pharmacol Exp Ther. 2005; 314: 932-938
76. Holmes E, Nicholls AW, Lindon JC, et al. Development of a model for classification of toxin-induced lesions using 1H NMR spectroscopy of urine combined with pattern recognition. NMR Biomed. 1998; 11: 235-244
77. Blackwood JK, Whittaker RG, Blakely EL, et al. The investigation and diagnosis of pathogenic mitochondrial DNA mutations in human urothelial cells. Biochem Biophys Res Commun. 2010; 393: 740-745
78. Whittaker RG, Blackwood JK, Alston CL, et al. Urine heteroplasmy is the best predictor of clinical outcome in the m.3243A4G mtDNA mutation. Neurology. 2009; 72: 568-569
79. Gagneux-Brunon A, Mariat C, Delanaye P. Cystatin C in HIV-infected patients: promising but not yet ready for prime time. Nephrol Dial Transplant. 2012; 27: 1305-1313
80. Koenig KF, Kalbermatter S, Menter T, et al. Recurrent bone fractures due to tenofovir-induced renal phosphate wasting. Scand J Infect Dis. 2014; 46: 221-224
81. Lapsley M, Akers K, Norden AG. Sensitive assays for urinary retinolbinding protein and beta-2-glycoprotein-1 based on commercially available standards. Ann Clin Biochem. 1998; 35(Pt 1): 115-119
82. Bradford MM A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248-254
83. Casado P, Cutillas PR A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments. Mol Cell Proteomics. 2011; 10: M110
84. Montoya A, Beltran L, Casado P, et al. Characterization of a TiO(2) enrichment method for label-free quantitative phosphoproteomics. Methods. 2011; 54: 370-378
85. Cutillas PR, Vanhaesebroeck B. Quantitative profile of five murine core proteomes using label-free functional proteomics. Mol Cell Proteomics. 2007; 6: 1560-1573
86. Beckonert O, Keun HC, Ebbels TM, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc. 2007; 2: 2692-2703
87. Lindon JC, Holmes E, Nicholson JK. Pattern recognition methods and applications in biomedical magnetic resonance. Prog Nucl Magn Reson Spectrosc. 2001; 39: 1-40